Cargando…

Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression

PURPOSE: Colorectal cancer (CRC) can develop via a hypermutagenic pathway characterized by frequent somatic DNA base-pair mutations. Alternatively, the immunogenicity of tumor cells themselves may influence the anticancer activity of the immune effector cells. Impaired DNA repair mechanisms drive mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Zhang, Xin, Jin, Zhuoyi, Chen, Huiyan, Zhang, Chenjing, Wang, wangyue, Jing, Jiyong, Pan, Wensheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559027/
https://www.ncbi.nlm.nih.gov/pubmed/34737598
http://dx.doi.org/10.2147/JIR.S331010
_version_ 1784592682442555392
author Zhang, Yu
Zhang, Xin
Jin, Zhuoyi
Chen, Huiyan
Zhang, Chenjing
Wang, wangyue
Jing, Jiyong
Pan, Wensheng
author_facet Zhang, Yu
Zhang, Xin
Jin, Zhuoyi
Chen, Huiyan
Zhang, Chenjing
Wang, wangyue
Jing, Jiyong
Pan, Wensheng
author_sort Zhang, Yu
collection PubMed
description PURPOSE: Colorectal cancer (CRC) can develop via a hypermutagenic pathway characterized by frequent somatic DNA base-pair mutations. Alternatively, the immunogenicity of tumor cells themselves may influence the anticancer activity of the immune effector cells. Impaired DNA repair mechanisms drive mutagenicity, which then increase the neoantigen load and immunogenicity. However, no studies have analyzed immune checkpoint protein expression, particularly programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), in adenoma–carcinoma progression and its relationship with the emergence of other DNA repair gene mutation. MATERIALS AND METHODS: We investigated mutations of 10 genes involved in DNA repair function: XRCC1, TP53, MLH1, MSH, KRAS, GSTP, UMP, MTHF, DPYD, and ABCC2. We performed sequencing to determine mutations and immunohistochemistry of immune checkpoints in clinical samples and determined changes in XRCC1 expression during progression through the adenoma–carcinoma pathway. We further investigated the prognostic associations of gene XRCC1 according to the expression, mutational profile, and immune profile using The Cancer Genome Atlas-colon adenocarcinoma (TCGA-COAD) dataset. RESULTS: From clinical samples, XRCC1 mutation demonstrated the strongest association with adenomas with a mutation frequency of 56.2% in adenomas and 34% in CRCs (p =0.016). XRCC1 was abnormally expressed and altered by mutations contributing to adenoma carcinogenesis. High expression of XRCC1, CD4, FOXP3, and PD-1/PD-L1 showed an overall upward trend with increased lesion severity (all p < 0.01). PD-1/PD-L1 expression and CD4+ intraepithelial lymphocytes (IELs) correlated with cytological dysplasia progression, specifically in patients with wild-type XRCC1 (all p < 0.01), whereas FOXP3 expression was independently associated with adenoma–carcinoma progression. From TCGA-COAD analysis, XRCC1 expression was associated with patients survival, tumor-infiltrating lymphocytes and immune marker expression. CONCLUSION: Increased IEL density and PD-1/PD-L1 expression correlate with cytological dysplasia progression and specifically with the XRCC1 mutation status in CRC. Our findings support a stepwise dysplasia-carcinoma sequence of adenoma carcinogenesis and an XRCC1 hypermutated phenotypic mechanism of lesions.
format Online
Article
Text
id pubmed-8559027
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85590272021-11-03 Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression Zhang, Yu Zhang, Xin Jin, Zhuoyi Chen, Huiyan Zhang, Chenjing Wang, wangyue Jing, Jiyong Pan, Wensheng J Inflamm Res Original Research PURPOSE: Colorectal cancer (CRC) can develop via a hypermutagenic pathway characterized by frequent somatic DNA base-pair mutations. Alternatively, the immunogenicity of tumor cells themselves may influence the anticancer activity of the immune effector cells. Impaired DNA repair mechanisms drive mutagenicity, which then increase the neoantigen load and immunogenicity. However, no studies have analyzed immune checkpoint protein expression, particularly programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), in adenoma–carcinoma progression and its relationship with the emergence of other DNA repair gene mutation. MATERIALS AND METHODS: We investigated mutations of 10 genes involved in DNA repair function: XRCC1, TP53, MLH1, MSH, KRAS, GSTP, UMP, MTHF, DPYD, and ABCC2. We performed sequencing to determine mutations and immunohistochemistry of immune checkpoints in clinical samples and determined changes in XRCC1 expression during progression through the adenoma–carcinoma pathway. We further investigated the prognostic associations of gene XRCC1 according to the expression, mutational profile, and immune profile using The Cancer Genome Atlas-colon adenocarcinoma (TCGA-COAD) dataset. RESULTS: From clinical samples, XRCC1 mutation demonstrated the strongest association with adenomas with a mutation frequency of 56.2% in adenomas and 34% in CRCs (p =0.016). XRCC1 was abnormally expressed and altered by mutations contributing to adenoma carcinogenesis. High expression of XRCC1, CD4, FOXP3, and PD-1/PD-L1 showed an overall upward trend with increased lesion severity (all p < 0.01). PD-1/PD-L1 expression and CD4+ intraepithelial lymphocytes (IELs) correlated with cytological dysplasia progression, specifically in patients with wild-type XRCC1 (all p < 0.01), whereas FOXP3 expression was independently associated with adenoma–carcinoma progression. From TCGA-COAD analysis, XRCC1 expression was associated with patients survival, tumor-infiltrating lymphocytes and immune marker expression. CONCLUSION: Increased IEL density and PD-1/PD-L1 expression correlate with cytological dysplasia progression and specifically with the XRCC1 mutation status in CRC. Our findings support a stepwise dysplasia-carcinoma sequence of adenoma carcinogenesis and an XRCC1 hypermutated phenotypic mechanism of lesions. Dove 2021-10-20 /pmc/articles/PMC8559027/ /pubmed/34737598 http://dx.doi.org/10.2147/JIR.S331010 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Yu
Zhang, Xin
Jin, Zhuoyi
Chen, Huiyan
Zhang, Chenjing
Wang, wangyue
Jing, Jiyong
Pan, Wensheng
Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression
title Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression
title_full Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression
title_fullStr Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression
title_full_unstemmed Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression
title_short Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma–Carcinoma Pathway Progression
title_sort clinical impact of x-ray repair cross-complementary 1 (xrcc1) and the immune environment in colorectal adenoma–carcinoma pathway progression
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559027/
https://www.ncbi.nlm.nih.gov/pubmed/34737598
http://dx.doi.org/10.2147/JIR.S331010
work_keys_str_mv AT zhangyu clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression
AT zhangxin clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression
AT jinzhuoyi clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression
AT chenhuiyan clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression
AT zhangchenjing clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression
AT wangwangyue clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression
AT jingjiyong clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression
AT panwensheng clinicalimpactofxrayrepaircrosscomplementary1xrcc1andtheimmuneenvironmentincolorectaladenomacarcinomapathwayprogression